Zolmitriptan Mouth Dissolving Tablets: Development of Formulas and Invitro Evaluation

Year : 2024 | Volume :01 | Issue : 02 | Page : 1-15

Uzma Fatima

k.yadava reddy

  1. Student Mak college of Pharmacy Hyderabad, Telangana India
  2. Associate professor Mak college of Pharmacy Hyderabad, Telangana India


Pharma Burst ODT super disintegrants were used in different concentrations to manufacture Zolmitriptan fast dissolving tablets by a direct compression method. With a 28° angle of repose, there is good flow. The densities for bulk and tapped materials are 0.410 (g/ml) and 0.500 (g/ml), respectively. The compressibility index and Hausner ratio have values of 19.05 and 1.24, correspondingly. According to IP standard, weight variation test results range from 121.4 mg to 126.1 mg. Friability: Less than 0.31%, according to the data, means that the percentage losses did not exceed 1.0% (complies with IP requirements). The thickness of the tablets ranges from 2.90 mm to 2.99 mm. Based on the results, it can be packed. There was a range of 98.62% to 100.3% content homogeneity. It was discovered that the tablet’s hardness ranged from 4 to 4.6 kg/cm2. The outcomes show that the tablets are within limit and have a solid mechanical structure. The disintegration time of the pills was found to be within a 30-second range, ranging from 0’11 to 0’16 seconds. For formulations FZ1, FZ2, FZ3, ZF4, FZ5, ZF6, FZ7, FZ8, and FZ9, a dissolution investigation was conducted in 6.8 pH phosphate buffer between 0 and 15 minutes. For formulations FZ9 and commercial product, a comparative dissolving analysis was conducted in phosphate buffer with a pH of 6.8. Tablet storage conditions: For 0, 30, 60, and 90 days, tablets were kept at 45°C ± 2°C/75%. The hardness of the tablets was gradually increased over time, but it was always within the permissible range. Disintegration time: varies depending on storage circumstances, but never exceeds 20 seconds, or less than 30 seconds (IP standard). The dissolving data of the formulations both at the beginning and after the designated storage period did not significantly alter, according to dissolution studies.

Keywords: Zolmitriptan, Fast dissolving tablets, Direct compression method, Disintegration time, Dissolution studies

[This article belongs to Emerging Trends in Personalized Medicines(etpm)]

How to cite this article: Uzma Fatima, k.yadava reddy. Zolmitriptan Mouth Dissolving Tablets: Development of Formulas and Invitro Evaluation. Emerging Trends in Personalized Medicines. 2024; 01(02):1-15.
How to cite this URL: Uzma Fatima, k.yadava reddy. Zolmitriptan Mouth Dissolving Tablets: Development of Formulas and Invitro Evaluation. Emerging Trends in Personalized Medicines. 2024; 01(02):1-15. Available from: https://journals.stmjournals.com/etpm/article=2024/view=134707

Browse Figures


  1. Aurora J. and Pathak V. Oral Disintegrating Technologies: Oral Disintegrating Dosage Forms: An Overview, Drug Deliv. Technol. 2005; 5 (3): 50–54.
  2. Bandari S. Orodispersible tablets An Overview, Asian J. Pharm.2008; 1: 2-11.
  3. Panigrahi D, Baghel S, and Mishra B. Mouth dissolving tablets:an overview of preparation techniques, evaluation and patentedtechnologies. J. Pharm. Res. 2004; 4(3):33–38.
  4. Ghosh T.K. “Orally Disintegrating Tablets,” AAPSNewsmagazine, 2004, 7 (6), 19-21.
  5. Pather S.I., Khankari R., and Siebert J,”Quick-DissolvingIntraoral Tablets,” in Drug Delivery to the Oral Cavity:Molecules to Market Ghosh T.K. and Pfister W.R., Eds. (CRCPress, New York, NY, 2005), pp. 291–336.
  6. Stetsko G. Statistical experimental design and its application to pharmaceutical development problems. Drug Dev Ind. Pharm. 1986; 12:1109-1123.
  7. Gohel M, Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004; 5:E36.
  8. Omaima A. Sammour, Formulation and Optimization of Mouth Dissolve Tablets Containing Rofecoxib Solid Dispersion. AAPS PharmSciTech 2006; 7 (2) Article 55 .
  9. Zaghloul A, Faltinek J, Reddy IK, Khan MA. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L 100-55. J Micro-encapsul. 2001; 18(5):651-662.
  10. Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:414.
  11. Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A: Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018 Jun;186:88-97. doi: 10.1016/j.pharmthera.2018.01.005. Epub 2018 Jan17.
  12. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S: Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr;97(2):553-622. doi: 10.1152/physrev.00034.2015.
  13. Becker WJ: Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. [Article]
  14. Feniuk W, Humphrey PP, Perren MJ, Connor HE, Whalley ET: Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol. 1991;238 Suppl 1:S57-61. doi: 10.1007/bf01642908.

Regular Issue Subscription Original Research
Volume 01
Issue 02
Received March 2, 2024
Accepted March 12, 2024
Published Mar 28, 2024